Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 183.51% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 183.51% | -- | -- | -- | -- |
| Cost of Revenue | 46.16% | -- | -- | -- | -- |
| Gross Profit | 315.51% | -- | -- | -- | -- |
| SG&A Expenses | -71.29% | -37.82% | -1.77% | 92.19% | 254.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.56% | -37.10% | 46.54% | 223.64% | 60.12% |
| Operating Income | 83.97% | 49.26% | -27.33% | -186.93% | -56.29% |
| Income Before Tax | 73.64% | 47.15% | -46.78% | -1,726.25% | -124.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.64% | 47.15% | -46.78% | -1,726.25% | -124.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -39.55% | -- | -- | -- | -- |
| Net Income | 73.67% | 47.20% | -46.73% | -1,725.99% | -123.99% |
| EBIT | 83.97% | 49.26% | -27.33% | -186.93% | -56.29% |
| EBITDA | 85.75% | 51.32% | -25.03% | -183.63% | -- |
| EPS Basic | 85.82% | 73.73% | 6.33% | -301.28% | 74.47% |
| Normalized Basic EPS | 83.29% | 73.71% | 6.36% | 67.38% | 78.70% |
| EPS Diluted | 85.82% | 73.73% | 6.33% | -301.28% | 74.47% |
| Normalized Diluted EPS | 83.29% | 73.71% | 6.36% | 67.38% | 78.70% |
| Average Basic Shares Outstanding | 85.80% | 100.91% | 56.63% | 322.48% | 777.44% |
| Average Diluted Shares Outstanding | 85.80% | 100.91% | 56.63% | 322.48% | 777.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |